50. Dermatomyositis
157 clinical trials,   207 drugs   (DrugBank: 76 drugs),   47 drug target genes,   142 drug target pathways

Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03857854
(ClinicalTrials.gov)
June 5, 201826/2/2019Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD)Dermatomyositis Interstitial Lung Disease (Dm-ILD)Drug: Pirfenidone;Drug: PlacebosBeijing Continent Pharmaceutical Co, Ltd.NULLRecruiting18 Years65 YearsAll152Phase 3China
2NCT02821689
(ClinicalTrials.gov)
July 201621/6/2016Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic DermatomyositisRandomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic DermatomyositisDermatopolymyositis;Interstitial Lung DiseaseDrug: PirfenidoneRenJi HospitalNULLNot yet recruiting16 YearsN/ABoth57Phase 4China
3ChiCTR-IPR-16007958
2014-06-012016-02-21An observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositisAn observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositis clinically amyopathic dermatomyositisRsearch group: glucocorticoids+immunosuppressant+pirfenidone;Control group: glucocorticoids+immunosuppressant;Renji Hospital, Shanghai Jiaotong University School of MedicineNULLCompletedBothRsearch group:30;Control group:30;China